Corporate History

2005
  • October 1, Sumitomo Dainippon Pharma created.
2006
  • AmBisome® (therapeutic agent for systemic fungal infection) launched.
2007
  • REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched.
  • The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd.
  • The mid-term business plan (for the period from fiscal 2007 to fiscal 2009) started.
2008
  • LONASEN® (atypical antipsychotic) launched.
  • AVAPRO® (therapeutic agent for hypertension) launched.
2009
  • TRERIEF® (Parkinson's disease drug) launched.
  • A holding company(Dainippon Sumitomo Pharma America Holdings, Inc.) established in the United States.
  • Acquired Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.), Sepracor (Current Sunovion Pharmaceuticals Inc.) became a wholly owned subsidiary of the U.S. holdings company.
    Sunovion Pharmaceuticals Inc.
    Sunovion Pharmaceuticals Inc.
2010
  • MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched.
  • The second mid-term business plan (for the period from fisical 2010 to fisical 2012) started.
  • Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) and Dainippon Sumitomo Pharma America, Inc. merged.
  • METGLUCO® (biguanide oral hypoglycemic) launched.
  • Growth hormone business transferred.
  • The Animal Health Products business split off and DS Pharma Animal Health Co., Ltd. established.
  • The Food & Speciality Products business integrated into its subsidiary Gokyo Trading Co., Ltd. and corporate name changed to DSP Gokyo Food & Chemical Co., Ltd.
  • Sepracor Inc. changed its company name to Sunovion Pharmaceuticals Inc.
2011
  • LATUDA® (atypical antipsychotic) launched in the United States by Sunovion Pharmaceuticals Inc.
  • SUREPOST® (rapid-acting insulin secretagogue) launched.
2012
  • Acquired Boston Biomedical, Inc.
    Boston Biomedical, Inc.
    Boston Biomedical, Inc.
  • ZETONNA® (therapeutic agent for allergic rhinitis) launched in the U.S. by Sunovion Pharmaceuticals Inc.
  • Sunovion Pharmaceuticals Inc. Acquired Elevation Pharmaceuticals, Inc.(Current SRD)
  • AIMIX® (therapeutic agent for hypertension) launched.
2013
  • A Subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte Ltd.) established in Singapore.
  • The third mid-term business plan (for the period from fisical 2013 to fisical 2017) started.
  • Dainippon Sumitomo Pharma Europe Ltd. changed its company name to Sunovion Pharmaceuticals Europe Ltd.
  • Joint venture company(Create Vassine Company,Ltd.) established.
  • An anti-cancer drugs sales subsidiary company(Boston Biomedical Pharma,Inc.) established in the U.S.
2014
  • Joint venture company (Sighregen K.K.) established.
  • Kobe Regenerative & Cellular Medicine Center (Current Regenerative & Cellular Medicine Kobe Center) opened.
    Kobe Regenerative & Cellular Medicine Center
    Regenerative & Cellular Medicine Kobe Center
  • APTIOM® (antiepileptic) launched in the United States by Sunovion Pharmaceuticals Inc.
  • LATUDA® (atypical antipsychotic) launched in the U.K.by Sunovion Pharmaceuticals Europe Ltd.
  • Announced reorganization of product sites (Integration of productive functions of Ibaraki Plant and Suzuka Plant, Closure of Ehime Plant)
2015
  • Started promotion for the indication "pruritus in chronic liver disease patients " of REMITCH®
  • Trulicity® (GLP-1 receptor agonist) launched.
2016
  • Sunovion Pharmaceuticals Inc. acquired Cynapsus Therapeutics Inc., a Canadian company (Current Sunovion CNS Development Canada ULC)
  • A Subsidiary for Promotion of Authorized Generics and others (DS Pharma Promo Co., Ltd.) established.
2017
  • Acquired Tolero Pharmaceuticals, Inc.
  • Boston Biomedical Pharma, Inc. integrated into its subsidiary Boston Biomedical, Inc. and corporate name changed to Boston Biomedical, Inc.
  • UTIBRON™(COPD product) launched in the U.S. by Sunovion Pharmaceuticals Inc.
  • Dainippon Sumitomo Pharma America Holdings, Inc. changed its company name to Sumitomo Dainippon Pharma America, Inc.